Table 5.

The HR for OS and PFS of PLR was pooled in subgroup analyses.

Subgroup	PFS				OS
	Study	HR [95%CI]	P value	I2	Study	HR [95%CI]	P value	I2
Country
China	4	1.47 (1.10,1.93)	0.009	0	5	1.63 (1.27,2.11)	P<0.001	0
Japan	1	1.63 (1.06,2.50)	0.026	NA	1	1.33 (0.81,2.15)	0.248	NA
Sample size
<100	3	1.66 (1.11,2.49)	0.017	14	3	1.77 (1.30,2.42)	0.06	0
≥100	2	1.44 (1.06,1.95)	0.012	0	3	1.36 (0.98,1.88)	P<0.001	0
cut-off
≥200	2	1.78 (1.14,2.80)	0.011	0	2	1.87 (1.18,2.97)	0.008	0
<200	3	1.42 (1.07,1.89)	0.015	6.6	3	1.41 (1.04,1.92)	0.026	0
Follow-up
≤15	1	1.63 (1.06,2.50)	0.026	NA	1	1.33 (0.81,2.15)	0.248	NA
>15	3	1.47 (1.10,1.97)	0.009	0	5	1.63 (1.27,2.11)	P<0.001	0
Combined medication
Monotherapy	1	1.98 (0.97,4.05)	0.059	NA	1	1.73 (0.82,3.87)	0.059	NA
Combined therapy	3	1.47 (1.13,1.89)	0.003	0	5	1.52 (1.20,1.93)	P<0.001	0

NA, Not Applicable.